Ray continued, “We’re also delighted to acknowledge Martin and Greg’s contributions to Synthekine with their new roles. Martin’s deep insights into cytokine biology and immunology were instrumental to shaping the development of STK-012, our first-in-course alpha/beta biased IL-2. Its one of a kind system expands the therapeutic index of IL-2, https://httpswwwzosanopharmacomte50493.atualblog.com/43058710/the-ultimate-guide-to-https-www-zosanopharma-com-technology